Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
69,596,826
-
Total 13F shares
-
30,093,340
-
Share change
-
+2,986,403
-
Total reported value
-
$333,317,526
-
Price per share
-
$11.08
-
Number of holders
-
85
-
Value change
-
+$38,491,787
-
Number of buys
-
47
-
Number of sells
-
36
Institutional Holders of Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) as of Q3 2022
As of 30 Sep 2022,
Phathom Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (PHAT) was held by
85 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,093,340 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., Medicxi Ventures Management (Jersey) Ltd, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Invesco Ltd., Avidity Partners Management LP, Ensign Peak Advisors, Inc, 683 Capital Management, LLC, BlackRock Inc., Abingworth LLP, and VANGUARD GROUP INC.
This page lists
85
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.